Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3 Lung Diseases 2 Lung Neoplasms 1 Carcinoma 1

Interventions

Cisplatin 16 pembrolizumab 15 Magnetic Resonance Spectroscopy 13 Specimen Handling 12 Carboplatin 11 Platinum 8 Paclitaxel 8 1,2-diaminocyclohexaneplatinum II citrate 8 durvalumab 6 Radiotherapy, Intensity-Modulated 6 Pemetrexed 6 Nivolumab 6 Cetuximab 6 cemiplimab 5 Radiotherapy 5 Radiation 5 Biopsy 5 Ipilimumab 4 Fluorouracil 4 Docetaxel 4 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4 (225)Ac-DOTA-c(RGDyK) 4 poly ICLC 3 osimertinib 3 atezolizumab 3 Taxes 3 Oxaliplatin 3 ipatasertib 2 fludarabine phosphate 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × zipalertinib × 90 days × Clear all

NCT05967689 2026-05-28

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡